Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PUR001 |
Synonyms | |
Therapy Description |
PUR001 is a monoclonal antibody that targets CD39, which may relieve adenosine-mediated immune suppression in the tumor microenvironment, resulting in enhanced antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PUR001 | PUR-001|PUR 001 | Adenosine Targeting 23 | PUR001 is a monoclonal antibody that targets CD39, which may relieve adenosine-mediated immune suppression in the tumor microenvironment, resulting in enhanced antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05234853 | Phase I | PUR001 | Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |